World’s First Long-Term Colorectal Cancer Model by 3D Bioprinting as a Mechanism for Screening Oncolytic Viruses
Author:
McGuckin Colin1ORCID, Forraz Nico1ORCID, Milet Clément1ORCID, Lacroix Mathieu1ORCID, Sbirkov Yordan2ORCID, Sarafian Victoria2ORCID, Ebel Caroline3, Spindler Anita3, Koerper Véronique3, Balloul Jean-Marc3, Quéméneur Eric3ORCID, Zaupa Cécile3
Affiliation:
1. CTIPharma Department, Cell Therapy Research Institute, CTIBIOTECH, Bat A16, 5 Avenue Lionel Terray, Meyzieu, 69330 Lyon, France 2. Department of Medical Biology and Research Institute, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria 3. Transgene, Illkirch-Graffenstaden, 67400 Strasbourg, France
Abstract
Long-term modelization of cancer as it changes in the human body is a difficult goal, particularly when designing and testing new therapeutic strategies. This becomes even more difficult with metastasis modeling to show chemotherapeutic molecule delivery directly to tumoral cells. Advanced therapeutics, including oncolytic viruses, antibody-based and cell-based therapies are increasing. The question is, are screening tests also evolving? Next-generation therapeutics need equally advanced screening tests, which whilst difficult to achieve, are the goal of our work here, creating models of micro- and macrotumors using 3D bioprinting. We developed advanced colorectal cancer tumor processing techniques to provide options for cellular expansion, microtumor printing, and long-term models, which allow for the evaluation of the kinetics of penetration testing, therapeutic success, targeted therapies, and personalized medicine. We describe how we tested tumors from a primary colorectal patient and, applying 3D bioprinting, matured long-term models for oncolytic metastatic screening. Three-dimensional microtumors were kept alive for the longest time ever recorded in vitro, allowing longitudinal studies, screening of oncolytic viruses and realistic modelization of colorectal cancer. These 3D bioprinted models were maintained for around 6 months and were able to demonstrate the effective delivery of a product to the tumoral environment and represent a step forward in therapeutic screening.
Funder
Fonds Unique Interministériel (FUI)—Banque Publique de l’Innovation (BPI) France, Metropoles of Lyon, and Grenoble, Lyonbiopole, Minalogic and La Région Auvergne-Rhône-Alpes Auvergne-Rhône Alpes Region for its production platform of microtumors by 3D-bioprinting for cancer research National Recovery and Resilience Plan of the Republic of Bulgaria
Subject
Cancer Research,Oncology
Reference38 articles.
1. Human organs-on-chips for disease modelling, drug development and personalized medicine;Ingber;Nat. Rev. Genet.,2022 2. Russomano, T., Cardoso, R., Falcao, F.P., Dalmarco, G., dos Santos, C.R.V., dos Santos, L.G.F., de Azevedo, D.F.G., dos Santos, M.A., Martinelli, L., and Motta, J.D. (2006, January 17–18). Development and Validation of a 3D Clinostat for the Study of Cells during Microgravity Simulation. Proceedings of the 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference, Shanghai, China. 3. 3D bioprinting in tissue engineering and regenerative medicine;Gupta;Cell Tissue Bank.,2022 4. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Siegel;CA Cancer J. Clin.,2021 5. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|